ArticleACS omega2023
Hydrocortisone-Loaded Lipid-Polymer Hybrid Nanoparticles for Controlled Topical Delivery: Formulation Design Optimization and In Vitro and In Vivo Appraisal.
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Effective topical delivery of minoxidil via chitosan coated nanocapsules to remodel microenvironment of dermal follicle for hair regeneration.Drug delivery and translational research · 2026Article
- Development and Optimization of 7,8-Dihydroxyflavone-Loaded Polylysine/Lecithin Nanoparticles for Potential Intranasal Delivery.Pharmaceutics · 2026Article
- Response0 surface guided design of lipid-polymer hybrid nanoparticles for dual delivery of rosuvastatin and ezetimibe.Discover nano · 2026Article
- Nanotechnology-based drug formulation and delivery systems for skin medical aesthetic dermatology: mechanisms, applications, and safety.Frontiers in pharmacology · 2026Review
- Advances in Lipid-Polymer Hybrid Nanoparticles: Design Strategies, Functionalization, Oncological and Non-Oncological Clinical Prospects.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Polymer- and Lipid-Based Nanostructures for Wound Healing with Barrier-Resolved Design.Pharmaceutics · 2025Review
- Topical and transdermal lipid-polymer hybrid nanoparticles (LPN): an integration in advancing dermatological treatments.Drug delivery and translational research · 2025Review
- In Vitro and In Vivo Appraisal of Glycerylmonostearate/chitosan Hybrid Nanocapsules As Peroral Delivery System of Simvastatin.AAPS PharmSciTech · 2025Article
- Oral Administration of Neratinib Maleate-Loaded Lipid-Polymer Hybrid Nanoparticles: Optimization, Physical Characterization, and In Vivo Evaluation.Pharmaceutics · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The barrier functionalities of the skin offer a major but not insuperable hindrance for fabrication of skin delivery effective systems. This work aimed to develop an optimized lipid polymer hybrid nanoparticle and assess the skin delivery effectiveness of hydrocortisone (9.872 ± 0.361 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.